We have located links that may give you full text access.
Fontan operation: influence of modifications on morbidity and mortality.
Annals of Thoracic Surgery 1994 October
The mortality rate of the Fontan operation for heart malformations with a single or dominant ventricle has been reduced by dividing the procedure into two stages. The hemi-Fontan procedure allows early reduction of the volume work of the single ventricle and remodeling of ventricular geometry before a completion Fontan operation. Despite the improvement of survival with this strategy (8% mortality for completion Fontan versus 16% mortality for primary Fontan operation), morbidity related to serous effusions remains substantial. Further technical modifications have been undertaken in an effort to reduce morbidity and further reduce mortality. From January 1990 through June 1993, 200 patients underwent completion Fontan procedures after previous hemi-Fontan operations. Mean age was 23 months, and 157 patients were less than 24 months of age. Diagnoses were hypoplastic left heart syndrome (127 patients), tricuspid atresia (19 patients), single left ventricle (17 patients), complex double-outlet right ventricle (16 patients), pulmonary atresia with intact ventricular septum (8 patients), and other (13 patients). Overall, early mortality rate was 8% (16 patients). In the last 112 patients, the procedure was modified technically by creating one or more fenestrations in the baffle used to separate systemic venous blood from pulmonary venous blood (36 patients), or by excluding one or more hepatic veins from the systemic venous pathway (76 patients). Early mortality for these 112 patients was reduced to 4.5% (5 patients). Substantial morbidity from serous effusions occurred at a rate of 45% (35 of 78 patients) among survivors who had received neither technical modification.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app